Atlantic Union Bankshares Corp Buys 2,110 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Atlantic Union Bankshares Corp increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 107,697 shares of the biopharmaceutical company’s stock after purchasing an additional 2,110 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Gilead Sciences were worth $9,948,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Avior Wealth Management LLC lifted its position in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 108 shares in the last quarter. Southland Equity Partners LLC increased its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the last quarter. Concord Asset Management LLC VA increased its holdings in shares of Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. Berkshire Bank increased its holdings in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the last quarter. Finally, TFB Advisors LLC increased its holdings in shares of Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 293,356 shares of company stock worth $29,166,240. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 1.2 %

NASDAQ:GILD opened at $117.41 on Friday. The firm has a market cap of $146.32 billion, a PE ratio of 317.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a fifty day moving average price of $99.61 and a 200 day moving average price of $91.39. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $118.42.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.69%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. UBS Group increased their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Finally, Citigroup initiated coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.24.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.